FDA
Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor
Sanofi's lunsekimig cleared asthma and nasal polyp trials but failed its eczema Phase 2, leaving Dupixent without a clear successor as its patent cliff nears.
Latest — Page 41
Deals
Apnimed Locks $150M Credit Line for AD109 Sleep Apnea Launch
Apnimed secured up to $150M from HCRx to launch AD109, with only $50M unconditional and the rest tied to FDA approval and a sales milestone.
Deals
Gilead Pays $3.15B for Tubulis in Third ADC Bet of 2026
Gilead's $3.15B upfront buy of Tubulis adds a 59%-ORR NaPi2b ADC to its pipeline — its third acquisition of 2026, totaling over $12B spent.
FDA
ImmunityBio Loses $2B in a Day After FDA Hits 'Cures Cancer' Pitch
FDA warned ImmunityBio after Chairman Patrick Soon-Shiong said Anktiva could 'cure cancer' on a podcast. Stock dropped 21%, $2B market cap gone.
Deals
Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race
Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.
deals
Deals
Takeda Files WARN for 634 US Cuts, 247 of Them at Cambridge HQ
Takeda filed a WARN notice to cut 634 US jobs, with 247 hitting its Cambridge headquarters — the largest concentration in the restructuring.
Deals
Syneron Bio Closes $150M Series B for Peptides
Syneron Bio raised a $150M Series B for peptide development. GLP-1s proved the format can print billions. The program list is still a mystery.
FDA
Makary's FDA Gets White House Backing to Fast-Track US Biotech vs. China
White House budget backs FDA policy shifts under Makary to speed US clinical trials and cut costs — framed as a direct counter to China's biotech ambitions.
Legal
Trump's 100% Pharma Tariffs Carve Out Half the Industry
Trump's 100% Section 232 pharma tariffs exempt 13 drugmakers, generics, and trade-deal nations. Mid-sized biotechs are most at risk. Exemptions expire 2029.
Deals
Neurocrine Buys Soleno for $2.9B, Betting 15x Revenue on Rare Hunger Drug
Neurocrine is paying $2.9B at ~15x trailing revenue for Soleno's Vykat XR, the only approved drug for Prader-Willi hunger, in its biggest-ever deal.
Deals
Anthropic Drops $400M on Six-Person Drug Discovery Startup
Anthropic acquires six-person AI biotech Coefficient Bio for $400M in stock — $66M per employee for a company founded in 2025 with no public product.
Deals
Takeda Walks Away From $150M Denali Dementia Bet After 8 Years
Takeda returns frontotemporal dementia drug DNL593 to Denali after 8 years and $150M, citing strategy—not safety—days after Denali's FDA approval win.
FDA
Amgen's $27.8B Drug Gets Easier — Tepezza Shot Matches IV
Amgen's phase 3 shows subcutaneous Tepezza via on-body injector hits 77% response rate, matching IV efficacy, potentially expanding the flat $1.9B drug's reach.
Deals
Anthropic Pays $400M for a 10-Person Ghost Company
Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.
Deals
Stipple Bio Raises $100M to Pinpoint Cancer Drug Targets
Stipple Bio launches with $100M to identify precise targets on cancer proteins, betting the ADC industry's real problem is aim, not ammo.
